CAM2029 (octreotide subcutaneous depot)

DRUG5 trials

Sponsors

Camurus AB

Conditions

AcromegalyPolycystic liver diseasegastroenteropancreatic neuroendocrine tumors

Phase 2

A randomized, placebo-controlled, double-blind, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver disease

Active, not recruitingCTIS2023-505313-24-00

Camurus ABPolycystic liver disease

Start: 2022-09-30Target: 31Updated: 2025-10-03

Phase 3

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

CompletedNCT04076462

Camurus ABAcromegaly

Start: 2019-08-19End: 2023-05-02Updated: 2024-04-25

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

CompletedNCT04125836

Camurus ABAcromegaly

Start: 2019-10-10End: 2025-04-24Updated: 2025-12-22

A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patients with gastroenteropancreatic neuroendocrine tumors

Active, not recruitingCTIS2023-508723-12-00

Camurus ABgastroenteropancreatic neuroendocrine tumors

Start: 2021-09-27Target: 234Updated: 2025-10-28

A Phase 3, open-label, single-arm, multi-center trial to assess the long-term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly

CompletedCTIS2024-510667-33-00

Camurus ABAcromegaly

Start: 2021-06-03End: 2025-04-24Target: 35Updated: 2025-02-04

Related Papers

SUN-097 CAM2029 Octreotide Subcutaneous Depot Maintains Control of IGF-I and Symptoms of Acromegaly Across the 4-Week Dosing Interval and During Intervals Greater Than 28 Days: Data from the ACROINNOVA 1 Trial

Journal of the Endocrine Society2025-10-01

Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.

2025-05-26

Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1

The Journal of Clinical Endocrinology & Metabolism2024-10-0815 citations

7373 CAM2029, Octreotide Subcutaneous Depot, Provides Sustained Biochemical Control of Acromegaly: Interim Results From a Phase 3 Study (ACROINNOVA 2)

Journal of the Endocrine Society2024-10-011 citations

7376 Efficacy and Safety of CAM2029 in Patients With Controlled or Inadequately Controlled Acromegaly on Standard-of-Care Treatment: Interim Data for the “New to CAM2029” Patient Subgroup in a Phase 3 Study (ACROINNOVA 2)

Journal of the Endocrine Society2024-10-011 citations

7377 CAM2029, Octreotide Subcutaneous Depot, Improves Patient-Reported Outcomes From Standard-of-Care Baseline in Patients With Acromegaly: Interim Results From a Phase 3 Study (ACROINNOVA 2)

Journal of the Endocrine Society2024-10-01

THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly

Journal of the Endocrine Society2023-10-011 citations